Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease
Explore this paper's citation graph
- Type
- article
- Published
- 2010-07-01
- Cited by
- 97
- References
- 71
- Access
- Open access
- OpenAlex
- https://openalex.org/W20456008
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:42497219
Keywords
Dividend, Econometrics, Mathematics, Actuarial science, Economics
References
- The rat brain in stereotaxic coordinates: Authors: George Paxinos & Charles Watson Academic Press Australia, 1982 Softback, 154 pages (including 71 plates), 35.00 Aust $
- Levodopa and the progression of Parkinson's disease.
- RNA editing of brain glutamate receptor channels: mechanism and physiology.
- Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity
- A Common Signaling Pathway for Striatal NMDA and Adenosine A2a Receptors: Implications for the Treatment of Parkinson's Disease
- L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
- Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia
- Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.
- The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
- Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
- Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease
- Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia
- AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
- Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study.
- Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
- Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS.
- NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
- Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
- Transient incorporation of native GluR2-lacking AMPA receptors during hippocampal long-term potentiation
- Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Cited by
- Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
- Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease
- A behavioural evaluation of the potential of nNOS inhibitors to control dyskinesia in animal models of Parkinson's disease
- Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.
- The β-lactam antibiotic ceftriaxone as a treatment for the symptoms of Parkinson’s disease and L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
- Optimisation and mechanistic insights of dyskinesia in rodent models of Parkinson’s disease
- New approaches to therapy.
- Maladaptive striatal plasticity in L-DOPA-induced dyskinesia
- Aberrant Restoration of Spines and their Synapses in l-DOPA-Induced Dyskinesia: Involvement of Corticostriatal but Not Thalamostriatal Synapses
- Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
- 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.
- Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
- Nitric oxide, a new player in L-DOPA-induced dyskinesia?
- Closing the gap between clinic and cage: sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease.
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
- Modeling dyskinesia in animal models of Parkinson disease.
- Gene Expression Analyses Identify Narp Contribution in the Development of l-DOPA-Induced Dyskinesia
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- Striatal Microcircuitry and Movement Disorders
- RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.